These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20205684)

  • 1. Current therapeutic paradigms in glioblastoma.
    Quick A; Patel D; Hadziahmetovic M; Chakravarti A; Mehta M
    Rev Recent Clin Trials; 2010 Jan; 5(1):14-27. PubMed ID: 20205684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repair mechanisms help glioblastoma resist treatment.
    Atkins RJ; Ng W; Stylli SS; Hovens CM; Kaye AH
    J Clin Neurosci; 2015 Jan; 22(1):14-20. PubMed ID: 25444993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
    Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
    Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
    Atif F; Patel NR; Yousuf S; Stein DG
    PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
    Johannessen TC; Bjerkvig R
    Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
    Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
    Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
    Thon N; Eigenbrod S; Grasbon-Frodl EM; Lutz J; Kreth S; Popperl G; Belka C; Kretzschmar HA; Tonn JC; Kreth FW
    J Neurol Neurosurg Psychiatry; 2011 Apr; 82(4):441-6. PubMed ID: 20861061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
    Franceschi E; Depenni R; Paccapelo A; Ermani M; Faedi M; Sturiale C; Michiara M; Servadei F; Pavesi G; Urbini B; Pisanello A; Crisi G; Cavallo MA; Dazzi C; Biasini C; Bertolini F; Mucciarini C; Pasini G; Baruzzi A; Brandes AA;
    J Neurooncol; 2016 May; 128(1):157-162. PubMed ID: 26943851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
    Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
    Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of elderly patients with glioblastoma: a systematic evidence-based analysis.
    Zarnett OJ; Sahgal A; Gosio J; Perry J; Berger MS; Chang S; Das S
    JAMA Neurol; 2015 May; 72(5):589-96. PubMed ID: 25822375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
    Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
    Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
    Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
    Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome.
    Wiewrodt D; Nagel G; Dreimüller N; Hundsberger T; Perneczky A; Kaina B
    Int J Cancer; 2008 Mar; 122(6):1391-9. PubMed ID: 18000822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
    Lombardi G; Rumiato E; Bertorelle R; Saggioro D; Farina P; Della Puppa A; Zustovich F; Berti F; Sacchetto V; Marcato R; Amadori A; Zagonel V
    Am J Clin Oncol; 2015 Oct; 38(5):514-9. PubMed ID: 24064758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
    Weller M; Wick W; Hegi ME; Stupp R; Tabatabai G
    Future Oncol; 2010 Sep; 6(9):1407-14. PubMed ID: 20919826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.